Ligand Pharmaceuticals

Quarterly Financials

Values in thousands 2024-12-31 2024-09-30 2024-06-30 2024-03-31
Revenue
$42,812
$51,812
$41,531
$30,978
Gross Profit
39,975
39,317
30,368
19,910
EBITDA
-29,690
3,143
-54,765
12,231
EBIT
-38,317
-5,851
-64,122
2,988
Net Income
-31,088
-7,172
-51,911
86,139
Net Change In Cash
42,812
51,812
41,531
30,978
Free Cash Flow
27,759
22,289
11,118
18,586
Cash
72,307
63,619
18,139
50,093
Basic Shares
18,974
18,419
18,028
18,122

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$167,133
$131,314
$196,245
$277,133
Gross Profit
156,059
96,265
143,418
214,957
EBITDA
40,794
101,727
54,407
133,161
EBIT
5,555
64,316
11,013
91,824
Net Income
-4,032
52,154
-5,219
57,138
Net Change In Cash
167,133
131,314
196,245
277,133
Cost of Revenue
-28,440
Free Cash Flow
95,226
-4,272
119,927
70,037
Cash
72,307
22,954
45
19,522
Basic Shares
18,290
17,757
16,868
17,246

Earnings Calls

Quarter EPS
2024-12-31
$1.27
2024-09-30
$1.84
2024-06-30
$1.40
2024-03-31
$1.20